` Comparison: MYD vs ATXS - Alpha Spread

MYD
vs
ATXS

Over the past 12 months, MYD has underperformed ATXS, delivering a return of -66% compared to the ATXS's +91 569% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
MYD
ATXS
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

MYD Intrinsic Value
15 EUR
Undervaluation 75%
Intrinsic Value
Price
ATXS Intrinsic Value
0.16 USD
Overvaluation 100%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Myriad Genetics Inc
DUS:MYD
3.7 EUR
Astria Therapeutics Inc
NASDAQ:ATXS
5 784.3 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
MYD, ATXS

MYD
ATXS
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Myriad Genetics Inc
Revenue
Astria Therapeutics Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
MYD, ATXS

MYD
ATXS
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Myriad Genetics Inc
DUS:MYD
Astria Therapeutics Inc
NASDAQ:ATXS
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

MYD
70.4%
ATXS
0%

Operating Margin

MYD
-9.9%
ATXS
-19 335.7%

Net Margin

MYD
-48.5%
ATXS
-17 568%

FCF Margin

MYD
-3.6%
ATXS
-17 042.9%

ROE

MYD
-72.5%
ATXS
-43.1%

ROA

MYD
-44.3%
ATXS
-39.2%

ROIC

MYD
-10.3%
ATXS
-462.1%

ROCE

MYD
-10.9%
ATXS
-45.9%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
MYD, ATXS

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MYD, ATXS

Loading
MYD
ATXS
Difference
www.alphaspread.com

Performance By Year
MYD, ATXS

Loading
MYD
ATXS
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare MYD to other stocks
PNEXF
Pharnext SCA
More expensive
vs MYD
ABBV
Abbvie Inc
More expensive
vs MYD
AMGN
Amgen Inc
More expensive
vs MYD
GILD
Gilead Sciences Inc
More expensive
vs MYD
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett